Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

A small molecule that blocks TYK2 in the brain showed promise for reducing disease activity in mouse models of multiple ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis ...

Columnist Ahna Crum spent years trying to go it alone. Now she knows that freedom comes when she's flocking together with ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...